MICHAEL R MIGDEN to Pyridines
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Pyridines.
Connection Strength
2.608
-
A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. J Drugs Dermatol. 2021 02 01; 20(2):156-165.
Score: 0.447
-
Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018 Mar; 14(6):515-525.
Score: 0.358
-
Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016 Sep; 12(18):2095-105.
Score: 0.323
-
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28.
Score: 0.301
-
Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. Eur J Dermatol. 2023 Jun 01; 33(3):280-286.
Score: 0.131
-
Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42?months. J Am Acad Dermatol. 2021 Apr; 84(4):1162-1164.
Score: 0.111
-
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020 06; 182(6):1369-1378.
Score: 0.103
-
Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. Dermatol Surg. 2019 01; 45(1):1-16.
Score: 0.097
-
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar; 32(3):372-381.
Score: 0.089
-
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 05 16; 17(1):332.
Score: 0.086
-
Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124.
Score: 0.084
-
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 09 01; 11(1):120.
Score: 0.082
-
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5.
Score: 0.080
-
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8.
Score: 0.075
-
Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2.
Score: 0.075
-
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 09; 27(3):327-41.
Score: 0.074
-
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9.
Score: 0.061
-
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857.
Score: 0.029